SCHEMBL4856868

SCHEMBL4856868

Cc1ccc2c(c1)CC=C2

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.35
CYP2A6 P11509 2/20 0.35
METAP1 P53582 1/20 0.33
PARP10 Q53GL7 1/20 0.32
PARP11 Q9NR21 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C19 P33261 1/20 0.32
TDP1 Q9NUW8 4/20 0.31
TRPA1 O75762 2/20 0.31
TP53 P04637 2/20 0.31
CYP3A4 P08684 1/20 0.31
THRB P10828 1/20 0.31
ALOX15 P16050 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
ACHE P22303 2/20 0.31
HTR5A P47898 1/20 0.31
NOTUM Q6P988 1/20 0.31
LMNA P02545 1/20 0.30
CHRM1 P11229 1/20 0.30
SLC6A2 P23975 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31513999 1.00 CYP1A2 (0.35) CYP1A2CYP2A6METAP1PARP10PARP11
SCHEMBL924413 0.82 CYP1A2 (0.35) CYP1A2CYP2A6METAP1PARP10CYP2D6
SCHEMBL2809898 0.80 CYP1A2 (0.33) CYP1A2CYP2A6METAP1PARP10PARP11
SCHEMBL17208908 0.78 ACHE (0.33) CYP3A4ACHEALDH1A1
SCHEMBL10565003 0.75 ALDH1A1 (0.37) CYP1A2CYP2A6METAP1PARP10PARP11
SCHEMBL275981 0.74 TUBB4A (0.30)
Indene SCHEMBL29142763 0.74 CA1 (0.46) CYP2D6CYP2C19ACHELMNAALDH1A1
SCHEMBL8675519 0.73 METAP1 (0.41) CYP1A2CYP2A6METAP1PARP10PARP11
SCHEMBL8031077 0.73 CA1 (0.33) CYP1A2CYP2A6HTR5ANOTUMALDH1A1
SCHEMBL7856986 0.73 MAPT (0.36) CYP3A4SMN1; SMN2LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250154172-A1 PRMT5 INHIBITORS AND USES THEREOF GILEAD SCIENCES, INC. 2025-05-15 US disclosed
EP-3897832-B1 N-(PYRIDIN-2-YLSULFONYL)CYCLOPROPANECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF A CFTR MEDIATED DISEASE NOVARTIS AG (CH) 2023-10-11 EP disclosed
CN-113402673-A Preparation method of chemically grafted polyacrylic acid bonded beta-naphthylacetic acid modified polypropylene composite material 安徽省利特环保技术有限公司 2021-09-17 CN disclosed
EP-3797775-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY Novartis AG (CH) 2021-03-31 EP disclosed
CN-112105654-A Curable resin mixture, curable resin composition, and cured product thereof 日本化药株式会社 2020-12-18 CN disclosed
EP-3167886-B1 COMPOSITIONS AND METHODS FOR TREATMENT OF MACULAR EDEMA NOVARTIS AG (CH) 2020-08-05 EP disclosed
WO-2020031935-A1 CURABLE RESIN MIXTURE, CURABLE RESIN COMPOSITION, AND CURED PRODUCT 日本化薬株式会社 2020-02-13 WO disclosed
EP-2850668-B1 HOLE TRANSPORT MATERIALS INCLUDING OLED APPLICATIONS NISSAN CHEMICAL CORP (JP) 2019-11-20 EP disclosed
EP-3167886-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF MACULAR EDEMA SARcode Bioscience Inc. (US) 2017-05-17 EP disclosed
US-7416833-B2 Photoresist undercoat-forming material and patterning process SHIN-ETSU CHEMICAL CO., LTD. (JP) 2008-08-26 US disclosed
US-5157182-A Conversion of ortho-ethyltoluene to indene AMOCO CORPORATION (US) 1992-10-20 US disclosed
EP-0505972-A2 Process for producing styrenic copolymer IDEMITSU KOSAN COMPANY LIMITED (JP) 1992-09-30 EP disclosed
WO-1991011468-A1 NEW THERMOPLASTIC ELASTOMERS THE UNIVERSITY OF AKRON (US) 1991-08-08 WO disclosed
US-5032653-A Catalysts EXXON CHEMICAL PATENTS, INC. (US) 1991-07-16 US disclosed
US-4946899-A CARBOCATIONIC POLYMERIZATION INVOLVING HOMOPOLYMERIZATION OF ELASTOMER FOLLOWED BY COPOLYMERIZATION TO ADD GLASSY SEGMENTS; FORMING LIVING POLYMERS WITH A METAL HALIDE, PROMOTER AND SOLVENT MIXTURE THE UNIVERSITY OF AKRON (US) 1990-08-07 US disclosed
EP-0349195-A2 Direct synthesis by cationic polymerization of nitrogen-containing polymers EXXON CHEMICAL PATENTS INC. (US) 1990-01-03 EP disclosed
US-4296111-A 7-Substituted methyl cephalosporins derivatives and analogues thereof MERCK & CO. INC. (US) 1981-10-20 US disclosed
US-4207323-A 6-Substituted methyl penicillins, derivatives and analogues thereof MERCK & CO., INC. (US) 1980-06-10 US disclosed
US-4150156-A ANTIBIOTICS MERCK & CO., INC. (US) 1979-04-17 US disclosed
US-4123528-A ANTIBIOTICS MERCK & CO., INC. (US) 1978-10-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250154172-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT9 CYP1A2 4408/4885CYP2A6 4369/4885METAP1 330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.